Summit Therapeutics Share Discussion Threads

[hugus maximus] 29/9/2016 15:02

Shiver my timbers!

[freedosh] 29/9/2016 14:59

111 on risers board but intriguingly Summit Germany at 160. Is someone being a bit nifty over there in the old EU?

[luminoso] 29/9/2016 14:49

ditto, someuwin.

[freedosh] 29/9/2016 14:48

only been open 16 minutes, Hugus. Just takes a foolish Prophet in his tea break to sell a few.
2 days correction was essential to form the rest of the handle.

[luminoso] 29/9/2016 14:48

Lull before the storm. All kinds of games get played over there, especially before London closes. Penny not dropped yet. Still in the loo after morning coffee ? Who knows.

[waterloo01] 29/9/2016 14:47

Details of the F6 formulation may be at possibly 21st International WMS Congress October 4-8 in Granada, Spain. Will we also get an enrolment update next week?

[someuwin] 29/9/2016 14:46

Bought a few more. Silly not to now.

[hugus maximus] 29/9/2016 14:45

But the NASDAQ share price has fallen away again?

[luminoso] 29/9/2016 14:36

Glyn could get a placement way at a premium, I would have thought, after this statement.

[freedosh] 29/9/2016 14:33

I had a window there but fully invested. Never mind - no need for a bigsam

[someuwin] 29/9/2016 14:32

Its game on!

[waterloo01] 29/9/2016 14:29

If they were to make a move, they would want to do so before we raise funds as once we have funds/RDZ deal we might be best waiting for some EZ read-out.

[luminoso] 29/9/2016 14:25

I like " main company " reference. Cambridge is Massachusetts not UK of course.
Edit. Its basically a statement of intent to swallow us up.

[waterloo01] 29/9/2016 14:22

But Kaye said he's also considering drugs that increase the body's ability to make a protein called utrophin, which is similar to dystrophin, the protein Exondys51 (which also goes by the generic name of eteplirsen) helps create. The main company working on a utrophin drug also has a Cambridge presence: Summit Therapeutics (Nasdaq: SMMT), which earlier this year got the go-ahead from the FDA to expand a mid-stage trial of its drug into the U.S.

"The approval of eteplirsen was really just the first step," said Kaye.

[luminoso] 29/9/2016 14:16

Prepare to repel boarders ! Absolutely.
Might lead to more interest this affy from the US investors....make it easier to get that funding away, eh Glyn ?

[freedosh] 29/9/2016 14:11

pirates on the starboard me hearties

[hugus maximus] 29/9/2016 14:04

Thanks Luminoso ... now edited. Narrative never been my strong point! You did see that I politely said "plucked"?

[luminoso] 29/9/2016 13:38

You forgot the 'low hanging' bit, Hugus !

[hugus maximus] 29/9/2016 13:29

Agree Luminous & Waterloo

Interesting to see that Glyn clearly has support from us PIs to go for a placement asap rather than hang about.

Knowing this will dilute our share price in a ratio of roughly say 30% ( at a "screw us all" £1 placement!)... we STILL wish they'd JUST GET ON WITH IT and look at any potential C Diff deal later from a position of strength.

If investors like Jim Mellon think a sell out to someone like Sarepta at £3 is an exciting proposition, we are sitting like a low hanging over ripe piece of fruit in a tree waiting to be plucked.

COME ON GLYN ... WHAT'S GOING ON?!

[luminoso] 29/9/2016 12:23

Absolutely, waterloo. I totally agree they should get on and raise some money now. Firstly it would strengthen our hand in negotiations over Ridzy. Unfunded as we are, we are weak in those negotiations. Secondly, it would unleash a lot of pent up demand in the US. There could be a massive rerating, even with substantial dilution.
I hope it is being arranged as we speak.

[waterloo01] 29/9/2016 11:43

If they are going to raise, unless it's directly tied to any RDZ deal (likely) they might be best to just get on with it. SRPT was heavily over subscribed so there is money around looking for a home in the space.

I note SRPT have started a placebo phase 3 in two further exons (I guess as it's placebo they will have a year or two of sales in case it's negative) but does highlight again that if we follow the same path that the FDA has opened up, then we could well get accelerated approval based on the current trial with the placebo follow on to confirm.